Supplementary Data from T-Cell Receptor Gene–Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy
ARTICLE ABSTRACT
Purpose: Adoptive therapy with genetically engineered T cells carrying redirected antigen specificity is a new option for the treatment of cancer. This approach is not yet available for metastatic renal cell carcinoma (RCC), due to the scarcity of therapeutically useful reagents. We analyzed tumor-infiltrating lymphocytes (TIL) from RCC to identify T-cell specificities with shared tumor-specific recognition to develop T-cell receptor (TCR)-engineered T lymphocytes for adoptive therapy of RCC.Experimental Design: We established a T-cell clone from TIL that recognized a human leukocyte antigen (HLA)-A2–restricted tumor antigen. The TCR α- and β-chain genes were isolated, modified by codon optimization and murinization, and retrovirally transduced into peripheral blood lymphocytes (PBL). A TCR-expressing indicator line (B3Z-TCR53) was established to screen for antigen prevalence in RCC, other malignancies, and normal cell counterparts.Results: TCR53-engineered PBL recapitulated the specificity of the TIL and showed tumor-specific HLA-A2–restricted effector activities (IFN-γ, tumor necrosis factor-α, interleukin-2, macrophage inflammatory protein-1β, cytotoxicity). PBL-TCR53 of healthy donors and RCC patients exhibited similar transduction efficiency, expansion, and polyfunctional profile. Using B3Z-TCR53 cells, 130 tumor and normal cells were screened and shared TCR53 peptide: MHC expression was found in >60% of RCC and 25% of tumor lines of other histology, whereas normal tissue cells were not recognized.Conclusions: To date, TCR53 is the only TCR with shared HLA-A2–restricted recognition of RCC. It fulfills the criteria for utilization in TCR gene therapy and advances T cell–based immunotherapy to patients with RCC and other malignancies expressing the TCR ligand. Clin Cancer Res; 16(8); 2333–43. ©2010 AACR.
